Tirzepatide is a dual GLP-1/GIP receptor agonist, which synergistically enhances -cell function, shown remarkable efficacy in lowering HbA1c and body weight in patients with type 2 diabetes and patients with obesity [13, 14]
Tirzepatide microdosing Tirzepatide targets both GLP-1 and GIP receptors
Stamler J, Wentworth D, Neaton JD
Some patients may experience bloating or abdominal distension, which can be mistaken for generalised fluid retention
From there, it goes straight to the liver via the portal vein for whats called "first-pass metabolism." The liver is the body's detoxification center, and it's ruthless with foreign compounds, often breaking them down before they ever reach the rest of the body
Second, volumization, placing hyaluronic acid, collagen biostimulators, or calcium hydroxylapatite into precise tissue planes to restore lost volume or augment baseline contour